Page 12 - Glenmark Pharmaceuticals

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The medicines are a therapeutic equivalent of Banzel®

Drugmaker Glenmark fourth quarter net profit up 6% at Rs 233.87 crore

The rise came on account of higher sales.

Nifty Pharma index hits all-time high; Sun Pharma scales 4-year high

Since April, the Nifty Pharma index has outperformed the market by surging 15 per cent, against 1.7 per cent gain in the Nifty50 index

Glenmark Pharma hits 23-month high on Glenmark Life Sciences IPO plan

ICICI Securities believe this is a positive development for the company and will lead to value unlocking for the shareholder

Glenmark Pharma arm files paperwork for IPO with market regulator

Glenmark Pharmaceuticals on Saturday said its wholly-owned arm Glenmark Life Sciences has filed paperwork to go public

Domestic growth trajectory to remain strong for Glenmark in near term

Debt reduction key if the stock is to fetch higher valuation multiples

Glenmark gets USFDA nod for generic high blood pressure drug

Drug firmGlenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator for its generic Diltiazem Hydrochloride extended release capsules used for treatment of high blood pressure. The company has received final approval from the United States Food & Drug Administration (USFDA) for Diltiazem Hydrochloride extended-release capsules USP, in the strengths of 60 mg, 90 mg, and 120 mg, Glenmark said in a statement. The product is a generic version of Biovail Laboratories Inc's Cardizem SR extended-release capsules in the same strengths, it added. The company has been granted a competitive generic therapy (CGT) designation for these capsules, therefore, with thisapproval, Glenmark is eligible for 180 days of CGT exclusivity upon commercial marketing, the statementsaid. According to IQVIA sales data for the 12-month period ending January 2021, the Cardizem SR extended-release capsules, 60 mg, 90 mg, and 120 mg market (including brand and all available ...

Glenmark Pharma signs Rohit Sharma as brand ambassador for Candid Powder

Drug major Glenmark Pharma on Friday said it has signed cricketer Rohit Sharma as brand ambassador for its product Candid Powder.

Asset monetisation, sales uptick in US key triggers for Glenmark Pharma

The India business is expected to post double digit growth in FY22

Glenmark Pharmaceuticals net profit up 30% at Rs 248.17 cr in Dec qtr

Glenmark on Friday reported a 30.04 percent rise in its consolidated net profit to Rs 248.17 crore for the quarter ended December 2020

Sensex ends volatile trade 12 pts up; RIL jumps 6% this week, ITC down 7%

On the sectoral front, the Nifty Metal index skid 1.7 per cent, followed by the Nifty FMCG index declined 1.5 per cent

Glenmark Pharma gets USFDA approval for nervous system stimulant drug

Glenmark Pharmaceuticals Ltd has been granted final approval by the United States Food and Drug Administration (USFDA) for Amphetamine Sulfate tablets USP

Glenmark Pharma gets tentative nod from USFDA for blood thinning drug

Drug major Glenmark Pharma on Monday said it has received tentative approval from the US health regulator for anticoagulant Dabigatran Etexilate capsules

Pharma shares gain; Natco, Glenmark, Syngene, Sequent Scientific up over 5%

Patient footfalls are gaining traction in healthcare units as demand from non-Covid-19 patients is gathering pace, according to a November 25 report by CARE Ratings.

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug

Drug major Glenmark Pharma on Tuesday said it has received tentative approval from the US health regulator for Axitinib tablets, used in the treatment of kidney cancer. The tentatively approved product is the generic version of Inlyta tablets of PF Prism CV. Glenmark Pharmaceuticals Inc, USA has received tentative approval by the United States Food & Drug Administration (USFDA) for Axitinib tablets in the strength of 1 mg and 5 mg, the company said in a regulatory filing. Quoting IQVIA sales data for the 12 months ending October 2020, Glenmark Pharma said the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately USD 518.8 million. Glenmark's current portfolio consists of 166 products authorised for distribution in the US market and 45 ANDA's pending approval with the USFDA.

Dr Reddy's to acquire select brands from Glenmark in Russia, Ukraine

Dr Reddy's Laboratories on Saturday said it had inked a pact with Glenmark Pharmaceuticals to acquire its select anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan

As refinancing risks ease, S&P affirms Glenmark Pharma's 'BB-' rating

The rating agency has a stable outlook on Glenmark Pharma's rating and also removed it from 'CreditWatch'

Glenmark Pharmaceuticals gets US FDA approval for Tacrolimus Capsules USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg, the generic version of Prograf®1 Capsules, 0.5 mg, 1 mg and 5 mg, of Astellas Pharm US, Inc.According to IQVIATM sales data for the 12 month period ending September 2020, the Prograf® Capsules, 0.5 mg, 1 mg and 5 mg market2 achieved annual sales of approximately USD 286.8 million*.Glenmark's current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.1 All brand names and trademarks are the property of their respective owners.2 Market includes brand and all available therapeutic equivalents* IQVIATM National Sales .

Pharma shares underperform in a firm market; Glenmark, Ipca Labs fall 6%

In the past month, the S&P BSE Healthcare index underperformed the market by falling 5 per cent, as compared to 5.4 per cent rise in the S&P BSE Sensex